SCHEMBL6783247

SCHEMBL6783247

COc1cc2c(Oc3c(F)c(F)c(F)c(F)c3F)ncnc2cc1OCCN1CCCC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.65
FLT4 P35916 8/20 0.65
FLT1 P17948 6/20 0.65
EGFR P00533 4/20 0.65
RET P07949 4/20 0.65
PDGFRB P09619 4/20 0.65
EPHB4 P54760 3/20 0.65
CSF1R P07333 3/20 0.65
FLT3 P36888 3/20 0.65
FGFR1 P11362 2/20 0.65
TEK Q02763 2/20 0.65
AURKB Q96GD4 2/20 0.65
PLK4 O00444 1/20 0.65
GAK O14976 1/20 0.65
EPHB6 O15197 1/20 0.65
RIPK2 O43353 1/20 0.65
ERN1 O75460 1/20 0.65
STK10 O94804 1/20 0.65
MAP4K4 O95819 1/20 0.65
CHEK2 O96017 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4026458 0.91 EGFR (0.57) KDRFLT4FLT1EGFRRET
SCHEMBL6783306 0.86 EGFR (0.61) KDRFLT4FLT1EGFRRET
SCHEMBL5501376 0.83 KDR (0.66) KDRFLT4FLT1EGFRRET
SCHEMBL4424919 0.83 KDR (0.60) KDRFLT4FLT1EGFRRET
SCHEMBL4377465 0.82 KDR (0.65) KDRFLT4FLT1EGFRRET
SCHEMBL30408124 0.82 FLT4 (0.61) KDRFLT4FLT1EGFRRET
SCHEMBL20547607 0.82 FLT4 (0.61) KDRFLT4FLT1EGFRRET
SCHEMBL23720684 0.80 FLT4 (0.60) KDRFLT4FLT1EGFRPDGFRB
SCHEMBL7838826 0.79 KDR (0.49) KDRFLT4FLT1EGFRRET
Cediranib SCHEMBL63147 0.79 KDR (1.00) KDRFLT4FLT1EGFRRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716847-B2 ANTIALLERGENS, ANTIINFLAMMATORY ASTRAZENECA AB (SE) 2004-04-06 US disclosed
US-6593333-B1 Processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases or medical conditions mediated by cytokines. Tumour Necrosis Factor (hereinafter TNF), for example TNF alpha , and various ASTRAZENECA AB (SE) 2003-07-15 US disclosed
EP-1117653-B1 QUINOLINE AND QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2003-02-05 EP disclosed